{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:44:02Z","timestamp":1791895442413,"version":"4.3.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:00:00Z","timestamp":1738195200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:00:00Z","timestamp":1738195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100006396","name":"Qazvin University of Medical Sciences","doi-asserted-by":"publisher","award":["IR.QUMS.REC.1400.362"],"award-info":[{"award-number":["IR.QUMS.REC.1400.362"]}],"id":[{"id":"10.13039\/501100006396","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Complement Med Ther"],"DOI":"10.1186\/s12906-025-04759-4","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T11:27:37Z","timestamp":1738236457000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["A randomized double-blind clinical trial investigating the effects of ellagic acid on glycemic status, liver enzymes, and oxidative stress in patients with non-alcoholic fatty liver disease"],"prefix":"10.1186","volume":"25","author":[{"given":"Sara","family":"Mighani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasoul","family":"Samimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamadreza Rashidi","family":"Nooshabadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Amir","family":"Farzam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein Khadem","family":"Haghighian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Javadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,30]]},"reference":[{"issue":"1","key":"4759_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/CM9.0000000000001263","volume":"134","author":"YX Xian","year":"2020","unstructured":"Xian YX, Weng JP, Xu F. MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy. Chin Med J. 2020;134(1):8\u201319.","journal-title":"Chin Med J"},{"issue":"6","key":"4759_CR2","doi-asserted-by":"publisher","first-page":"100346","DOI":"10.1016\/j.jhepr.2021.100346","volume":"3","author":"L Parlati","year":"2021","unstructured":"Parlati L, R\u00e9gnier M, Guillou H, Postic C. New targets for NAFLD. JHEP Reports: Innov Hepatol. 2021;3(6):100346.","journal-title":"JHEP Reports: Innov Hepatol"},{"key":"4759_CR3","doi-asserted-by":"crossref","unstructured":"Aghakhani L, Haghighat N. The risk factors of nonalcoholic fatty liver disease in morbidly obese patients undergoing bariatric surgery in Iran. 2022;2022:5980390.","DOI":"10.1155\/2022\/5980390"},{"key":"4759_CR4","doi-asserted-by":"crossref","unstructured":"Mantovani A, Scorletti E, Mosca A, Alisi A, Byrne CD, Targher G. Complications, morbidity and mortality of nonalcoholic fatty liver disease. Metabolism Clin Exp. 2020;111:154170.","DOI":"10.1016\/j.metabol.2020.154170"},{"issue":"2","key":"4759_CR5","doi-asserted-by":"publisher","first-page":"206","DOI":"10.2741\/4892","volume":"26","author":"S Raza","year":"2021","unstructured":"Raza S, Rajak S, Upadhyay A, Tewari A, Anthony R, Sinha. Current treatment paradigms and emerging therapies for NAFLD\/NASH. Front Bioscience (Landmark Edition). 2021;26(2):206\u201337.","journal-title":"Front Bioscience (Landmark Edition)"},{"issue":"2","key":"4759_CR6","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s13340-022-00616-8","volume":"14","author":"Y Imi","year":"2023","unstructured":"Imi Y, Ogawa W, Hosooka T. Insulin resistance in adipose tissue and metabolic diseases. Diabetol Int. 2023;14(2):119\u201324.","journal-title":"Diabetol Int"},{"key":"4759_CR7","unstructured":"Arroyave-Ospina JC, Wu Z, Geng Y. Role of oxidative stress in the pathogenesis of non-alcoholic fatty liver disease. Implications Prev Therapy. 202;110(2)."},{"key":"4759_CR8","doi-asserted-by":"crossref","unstructured":"Tang G, Xu Y, Zhang C, Wang N, Li H. Green tea and epigallocatechin gallate (EGCG) for the management of nonalcoholic fatty liver diseases (NAFLD): insights into the role of oxidative stress and antioxidant Mechanism. 2021;10(7).","DOI":"10.3390\/antiox10071076"},{"key":"4759_CR9","doi-asserted-by":"crossref","unstructured":"Monserrat-Mesquida M, Quetglas-Llabr\u00e9s M, Abbate M, Montemayor S, Mascar\u00f3 CM. Oxidative stress and pro-inflammatory status in patients with non-alcoholic fatty liver disease. Antioxid. 2020;9(8):759.","DOI":"10.3390\/antiox9080759"},{"key":"4759_CR10","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.clnesp.2020.09.028","volume":"41","author":"A Salehi-Sahlabadi","year":"2021","unstructured":"Salehi-Sahlabadi A, Teymoori F, Jabbari M, Momeni A, Mokari-Yamchi A, Sohouli M, Hekmatdoost A. Dietary polyphenols and the odds of non-alcoholic fatty liver disease: a case-control study. Clin Nutr ESPEN. 2021;41:429\u201335.","journal-title":"Clin Nutr ESPEN"},{"key":"4759_CR11","doi-asserted-by":"crossref","unstructured":"Ma Y, Lee G, Heo SY, Roh YS. Oxidative stress is a key modulator in the development of nonalcoholic fatty liver disease. Antioxid (Basel Switzerland). 2021;11(1).","DOI":"10.3390\/antiox11010091"},{"key":"4759_CR12","doi-asserted-by":"publisher","first-page":"111819","DOI":"10.1016\/j.foodres.2022.111819","volume":"161","author":"J Duan","year":"2022","unstructured":"Duan J, Pan J, Sun M, Fang Y. Comparative multiomics study of the effects of ellagic acid on the gut environment in young and adult mice. Food Res Int (Ottawa Ont). 2022;161:111819.","journal-title":"Food Res Int (Ottawa Ont)"},{"key":"4759_CR13","doi-asserted-by":"crossref","unstructured":"Alexova R, Alexandrova S. Anti-COVID-19 potential of ellagic acid and polyphenols of Punica granatum L. Mol. 2023;28(9):3772.","DOI":"10.3390\/molecules28093772"},{"key":"4759_CR14","doi-asserted-by":"crossref","unstructured":"Aishwarya V, Solaipriya S, Sivaramakrishnan V. Role of ellagic acid for the prevention and treatment of liver diseases. Phytother Res. 2021;35(6):2925\u201344.","DOI":"10.1002\/ptr.7001"},{"key":"4759_CR15","doi-asserted-by":"crossref","unstructured":"Alfei S, Marengo B. Oxidative stress, antioxidant capabilities, and bioavailability: Ellagic acid or urolithins? Antioxid. 2020;9(8):707.","DOI":"10.3390\/antiox9080707"},{"key":"4759_CR16","doi-asserted-by":"crossref","unstructured":"JZ AL, Alshammari GM. Ellagic acid protects against non-alcoholic fatty liver disease in streptozotocin-diabetic rats by activating AMPK. Pharm Biol. 2022;60(1):25\u201337.","DOI":"10.1080\/13880209.2021.1990969"},{"key":"4759_CR17","doi-asserted-by":"crossref","unstructured":"Ghadimi M, Foroughi F, Hashemipour S, Rashidi Nooshabadi M, Ahmadi MH, Ahadi Nezhad B. H. Khadem Haghighian, Randomized double-blind clinical trial examining the ellagic acid effects on glycemic status, insulin resistance, antioxidant, and inflammatory factors in patients with type 2 diabetes. Phytother Res. 2021;35(2):1023\u201332.","DOI":"10.1002\/ptr.6867"},{"key":"4759_CR18","unstructured":"Weir CB, Jan A. BMI classification percentile and cut off points, StatPearls, StatPearls Publishing Copyright \u00a9 2023, StatPearls Publishing LLC., Treasure Island (FL) ineligible companies. Disclosure: Arif Jan declares no relevant financial relationships with ineligible companies; 2023."},{"issue":"5","key":"4759_CR19","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1123\/jpah.5.5.746","volume":"5","author":"KY Wolin","year":"2008","unstructured":"Wolin KY, Heil DP, Askew S, Matthews CE, Bennett GG. Validation of the international physical activity questionnaire-short among blacks. J Phys Act Health. 2008;5(5):746\u201360.","journal-title":"J Phys Act Health"},{"issue":"1\u20132","key":"4759_CR20","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jns.2011.12.008","volume":"315","author":"D Bosco","year":"2012","unstructured":"Bosco D, Plastino M, Cristiano D, Colica C, Ermio C, De Bartolo M, Mungari P, Fonte G, Consoli D, Consoli A, Fava A. Dementia is associated with insulin resistance in patients with Parkinson\u2019s disease. J Neurol Sci. 2012;315(1\u20132):39\u201343.","journal-title":"J Neurol Sci"},{"key":"4759_CR21","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.clinbiochem.2018.10.011","volume":"64","author":"MK Palmer","year":"2019","unstructured":"Palmer MK, Barter PJ, Lundman P, Nicholls SJ, Toth PP, Karlson BW. Comparing a novel equation for calculating low-density lipoprotein cholesterol with the Friedewald equation: a VOYAGER analysis. Clin Biochem. 2019;64:24\u20139.","journal-title":"Clin Biochem"},{"key":"4759_CR22","doi-asserted-by":"crossref","unstructured":"Sharma V, Singh TG. Therapeutic implications of glucose transporters (GLUT) in cerebral ischemia. Neurochem Res. 2022;47(8):2173\u201386.","DOI":"10.1007\/s11064-022-03620-1"},{"key":"4759_CR23","doi-asserted-by":"crossref","unstructured":"Khajebishak Y, Payahoo L. Effect of pomegranate seed oil supplementation on the GLUT-4 gene expression and glycemic control in obese people with type 2 diabetes: a randomized controlled clinical trial. J Cell Physiol. 2019;234(11):19621\u20138.","DOI":"10.1002\/jcp.28561"},{"key":"4759_CR24","doi-asserted-by":"crossref","unstructured":"Olvera-Sandoval C, Fabela-Illescas HE, Fern\u00e1ndez-Mart\u00ednez E. Potential mechanisms of the improvement of glucose homeostasis in type 2. Diabetes Pomegranate Juice. 2022;11(3).","DOI":"10.3390\/antiox11030553"},{"issue":"6","key":"4759_CR25","doi-asserted-by":"publisher","first-page":"3410","DOI":"10.1039\/C9FO00284G","volume":"10","author":"C Zhang","year":"2019","unstructured":"Zhang C, Hu J, Sheng L, Yuan M, Wu Y, Chen L, Wang G, Qiu Z. Ellagic acid ameliorates AKT-driven hepatic steatosis in mice by suppressing de novo lipogenesis via the AKT\/SREBP-1\/FASN pathway. Food Funct. 2019;10(6):3410\u201320.","journal-title":"Food Funct"},{"key":"4759_CR26","doi-asserted-by":"crossref","unstructured":"Huang J, Sigon G, Mullish BH. Applying lipidomics to non-alcoholic fatty liver disease: a clinical perspective. 2023;15(8).","DOI":"10.3390\/nu15081992"},{"key":"4759_CR27","doi-asserted-by":"crossref","unstructured":"Ling Q., Mao S, Pan J, Wei W, Qian Y, Li F, Huang S, Ye W, Lin X, Huang J, Wang J, Jin J. CPT1B, a metabolic molecule, is also an independent risk factor in CN-AML. Cancer Biomark A. 2023;37(3):133\u201345.","DOI":"10.3233\/CBM-210043"},{"key":"4759_CR28","doi-asserted-by":"publisher","first-page":"751501","DOI":"10.3389\/fphys.2021.751501","volume":"12","author":"Q Xu","year":"2021","unstructured":"Xu Q, Li S, Tang W, Yan J, Wei X, Zhou M, Diao H. The effect of ellagic acid on hepatic lipid metabolism and antioxidant activity in mice. Front Physiol. 2021;12:751501.","journal-title":"Front Physiol"},{"issue":"111","key":"4759_CR29","first-page":"30","volume":"20","author":"G Ekhlasi","year":"2013","unstructured":"Ekhlasi G, Shidfar F, Agah S, Merat S, Hosseini KAF. Effect of pomegranate juice intake on lipid profile in patients with non-alcoholic fatty liver disease. Razi J Med Sci. 2013;20(111):30\u20139.","journal-title":"Razi J Med Sci"},{"key":"4759_CR30","doi-asserted-by":"crossref","unstructured":"Karimi MY, Fatemi I. Ellagic acid prevents oxidative stress, inflammation, and histopathological alterations in acrylamide-induced hepatotoxicity in Wistar rats. J Diet Suppl. 2020;17(6):651\u201362.","DOI":"10.1080\/19390211.2019.1634175"},{"key":"4759_CR31","doi-asserted-by":"crossref","unstructured":"Kazemi M, Lalooha F. Randomized double blind clinical trial evaluating the ellagic acid effects on insulin resistance, oxidative stress and sex hormones levels in women with polycystic ovarian syndrome. J Ovarian Res. 2021;14:1\u20132.","DOI":"10.1186\/s13048-021-00849-2"},{"key":"4759_CR32","doi-asserted-by":"crossref","unstructured":"Masarone M, Rosato V, Dallio M, Gravina AG. Role of oxidative stress in pathophysiology of nonalcoholic fatty liver disease. 2018;2018:9547613.","DOI":"10.1155\/2018\/9547613"},{"key":"4759_CR33","doi-asserted-by":"crossref","unstructured":"Polce SA, Burke C, Fran\u00e7a LM. Ellagic acid alleviates hepatic oxidative stress and insulin resistance in diabetic female rats. Nutr. 2018;10(5):531.","DOI":"10.3390\/nu10050531"},{"issue":"6","key":"4759_CR34","doi-asserted-by":"publisher","first-page":"e13217","DOI":"10.1111\/jfbc.13217","volume":"44","author":"A Aslan","year":"2020","unstructured":"Aslan A, Gok O, Beyaz S, Arslan E, Erman O, A\u011fca CA. The preventive effect of ellagic acid on brain damage in rats via regulating of Nrf-2, NF-kB and apoptotic pathway. J Food Biochem. 2020;44(6):e13217.","journal-title":"J Food Biochem"}],"container-title":["BMC Complementary Medicine and Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-025-04759-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12906-025-04759-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-025-04759-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T11:27:45Z","timestamp":1738236465000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccomplementalternmed.biomedcentral.com\/articles\/10.1186\/s12906-025-04759-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,30]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4759"],"URL":"https:\/\/doi.org\/10.1186\/s12906-025-04759-4","relation":{},"ISSN":["2662-7671"],"issn-type":[{"value":"2662-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,30]]},"assertion":[{"value":"7 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol of the study after approving with the ethic committee of Qazvin University of Medical Sciences (ethic code: IR.QUMS.REC.1400.362), Qazvin, Iran, was registered in the Iranian Registry of Clinical Trials website by the IRCT20141025019669N21 code. Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors state they have no conflict of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"33"}}